Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

对于那些无法接受大剂量化疗（IC）和后续干细胞移植的 AML 患者来说，治疗选择十分有限。目前，他们通常接受低甲基化药物（HMA）的非强化治疗。然而，HMA 单药治疗并不能治愈疾病，只是延长患者的生存时间，且治疗会持续到疾病进展。 现有的欧洲白血病网 ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of ...